Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

As of 23 December at 1:01:52 pm GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 27 December at 12:58:04 pm GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 2:48 PM EST. Market Open.

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PFE surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past month, the stock has declined 4.3% to close the last trading session at $25.58. The average analyst ...